Antibody-blocking of CD44 or/and CD155 significantly inhibited invasion of the GBM cells studied, compared with their wild type counterparts (control) (p<0.0001; represented by SNB-19 in Fig. 3a/left panel). This evidence concerns the gene CD44 and glioblastoma.